Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant

Greg Monohan

Status and phase: Terminated; Phase 2

Conditions: Hodgkin's Lymphoma; Multiple Myeloma; Non-Hodgkin's Lymphoma

Treatments: Dietary Supplement: Nestle Impact Advanced Recovery

Study type: Interventional

Funder types: Other

Identifiers

NCT01699581

11-HEM-03-MCC

Details and patient eligibility

About

Nestle Impact has shown efficacy in multiple surgical trials in relation to improving hospital length of stay and infection rate. 1 dose of Nestle Impact Advanced Recovery will be taken orally three times a day beginning on the morning following stem cell transplant and will continue until the day of hospital discharge.

Enrollment: 35 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients receiving an autologous stem cell transplant using the preparative regimens of BEAM (Carmustine, Etoposide, Cytarabine, Melphalan), Melphalan 140mg/m2, or Melphalan 200mg/m2
• Any prior diet or supplement will be allowed.
• Age >18 years.
• Ability to understand and the willingness to sign a written informed consent document.

Exclusion criteria

• History of allergic reactions attributed to compounds of similar chemical or biologic composition to Nestle Impact including fish oil.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

35 participants in 1 patient group

Nestle Impact Advanced Recovery

Experimental group

Description:

Nestle Impact Advanced Recovery 1 dose of Nestle Impact Advanced Recovery orally three times a day

Treatment:

Dietary Supplement: Nestle Impact Advanced Recovery